Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
COR 
Cencora Inc. (COR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: COR (3-star) is a STRONG-BUY. BUY since 111 days. Profits (17.93%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $323.16
1 Year Target Price $323.16
| 10 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 39.81% | Avg. Invested days 65 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 57.24B USD | Price to earnings Ratio 34.14 | 1Y Target Price 323.16 |
Price to earnings Ratio 34.14 | 1Y Target Price 323.16 | ||
Volume (30-day avg) 17 | Beta 0.57 | 52 Weeks Range 217.25 - 308.75 | Updated Date 07/2/2025 |
52 Weeks Range 217.25 - 308.75 | Updated Date 07/2/2025 | ||
Dividends yield (FY) 0.73% | Basic EPS (TTM) 8.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.55% | Operating Margin (TTM) 1.34% |
Management Effectiveness
Return on Assets (TTM) 2.97% | Return on Equity (TTM) 141.78% |
Valuation
Trailing PE 34.14 | Forward PE 16.98 | Enterprise Value 63120036415 | Price to Sales(TTM) 0.18 |
Enterprise Value 63120036415 | Price to Sales(TTM) 0.18 | ||
Enterprise Value to Revenue 0.2 | Enterprise Value to EBITDA 16.99 | Shares Outstanding 193823008 | Shares Floating 183411289 |
Shares Outstanding 193823008 | Shares Floating 183411289 | ||
Percent Insiders 5.31 | Percent Institutions 93.91 |
Analyst Ratings
Rating 3 | Target Price 323.16 | Buy 1 | Strong Buy 10 |
Buy 1 | Strong Buy 10 | ||
Hold 5 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cencora Inc.
Company Overview
History and Background
Cencora Inc., formerly AmerisourceBergen, was founded in 2001 through the merger of Bergen Brunswig and AmeriSource Health Corporation. It has grown to become a leading global pharmaceutical distributor, providing drug distribution and related healthcare services. It has expanded through acquisitions and organic growth.
Core Business Areas
- Pharmaceutical Distribution Services: Distributes a comprehensive range of brand-name and generic pharmaceuticals, specialty pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies.
- Healthcare Solutions: Offers services such as inventory management, pharmacy automation, and data analytics to healthcare providers and pharmaceutical manufacturers.
- International Healthcare Solutions: Provides pharmaceutical wholesale, distribution and commercial solutions to pharmaceutical manufacturers, pharmacies and healthcare providers in Europe and other selected geographies.
Leadership and Structure
Steven H. Collis is the current Chairman, President and Chief Executive Officer. Cencora operates with a corporate structure divided into business segments, each managed by executive leadership, reporting to the CEO.
Top Products and Market Share
Key Offerings
- Brand-name Pharmaceuticals: Distribution of brand-name prescription drugs. Accounts for a large portion of Cencora's revenue. Competitors include McKesson, Cardinal Health.
- Generic Pharmaceuticals: Distribution of generic prescription drugs, offering cost-effective alternatives. Competitors include McKesson, Cardinal Health.
- Specialty Pharmaceuticals: Distribution of specialty pharmaceuticals, including oncology and immunology drugs, which often have complex handling requirements. Competitors include McKesson, Cardinal Health, and specialty pharmacies.
Market Dynamics
Industry Overview
The pharmaceutical distribution industry is characterized by high volume, low margins, and intense competition. It is heavily regulated and influenced by factors such as drug pricing, healthcare reform, and supply chain security.
Positioning
Cencora is one of the top three largest pharmaceutical distributors in the US, along with McKesson and Cardinal Health. Its competitive advantages include its scale, established relationships with manufacturers and pharmacies, and comprehensive service offerings.
Total Addressable Market (TAM)
The global pharmaceutical distribution market is estimated to be hundreds of billions of dollars. Cencora is positioned to capture a significant portion through its market presence.
Upturn SWOT Analysis
Strengths
- Large scale and market share
- Established relationships with manufacturers and pharmacies
- Comprehensive product and service offerings
- Global reach
Weaknesses
- Low profit margins
- Reliance on a few large customers
- Exposure to regulatory changes
- Debt levels from Acquisitions
Opportunities
- Growth in specialty pharmaceuticals
- Expansion into emerging markets
- Increased demand for healthcare services
- Technological advancements in supply chain management
Threats
- Drug pricing pressures
- Increased competition
- Supply chain disruptions
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- MCK
- CAH
Competitive Landscape
Cencora faces intense competition from McKesson and Cardinal Health. Cencora's strengths include its scale and established relationships. Weaknesses include low profit margins and exposure to regulatory changes.
Major Acquisitions
PharmaLex
- Year: 2020
- Acquisition Price (USD millions): 1280
- Strategic Rationale: Expanded Cencora's presence in specialty services and provided global regulatory expertise.
Growth Trajectory and Initiatives
Historical Growth: Cencora has grown historically through acquisitions and organic growth in the pharmaceutical distribution market. Requires data update.
Future Projections: Future growth depends on factors such as market trends, acquisitions, and new service offerings. Requires data update.
Recent Initiatives: Recent strategic initiatives may include acquisitions, partnerships, or investments in new technologies. Requires data update.
Summary
Cencora is a major player in the pharmaceutical distribution industry. Its strengths lie in its size and established relationships, but it faces challenges like low profit margins and regulatory risks. The company is well-positioned to capitalize on growth in specialty pharmaceuticals, but must navigate competitive pressures and drug pricing concerns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market conditions and company performance can change, so conduct thorough research before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cencora Inc.
Exchange NYSE | Headquaters Conshohocken, PA, United States | ||
IPO Launch date 1995-04-04 | President, CEO & Director Dr. Robert P. Mauch Ph.D., PharmD | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 42000 | Website https://www.cencora.com |
Full time employees 42000 | Website https://www.cencora.com | ||
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.